Despite mass level vaccinations and the launch of several repurposed drugs, the recently emerged SARS CoV-2 Omicron (B.1.1.529) is a variant of concern. New drugs must be discovered with artificial intelligence (AI) assistance. Artificial intelligence (AI) enabled drug repurposing reduces the time and costs of drug discovery. Ruxolitinib (formerly known as INCB018424; Jakavi; Jakafi) is an oral inhibitor of JAK 1 & 2. Ruxolitinib has been approved to treat primary myelofibrosis, polycythemia vera, and hemophagocytic lymphohistiocytosis by the Food and Drug Administration and European Medicines Agency. The analysis of ruxolitinib is done via the CoV-DrugX pipeline. We find that the Ruxolitinib has a 75% probability of being considered a COVID-19 repurposed drug with the help of the CoV-DrugX pipeline. In addition, there is a clinical trial assessing the safety and efficacy of ruxolitinib. Therefore, we believe that Ruxolitinib could be a potent drug against the treatment of COVID-19.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.